TGA Of Australia Eyes U.S. Counterpart's Avandia Decisions
This article was originally published in PharmAsia News
Executive Summary
Australia's Therapeutic Goods Administration, which already had ordered increased warnings on the labels for GlaxoSmithKline's Avandia (rosiglitazone) diabetes drug, is watching U.S. actions before taking further action